Assignee
BIOTHEUS INC
CN·4 granted patents·16 pending applications·0 citations·filing 2020–2025
Top patents by PatentIndex Score
20 records- 0160US2025223340A1Anti-serum albumin nanobody and derivative thereofBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 0260US2025297034A1Anti-vegf-anti-pd-l1 bispecific antibody, pharmaceutical composition of same, and uses thereofBIOTHEUS INC·Filed 2025·Application pending·0 cites
- 0360US2025223366A1Monoclonal antibodies and bispecific antibody against c-metBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 0459US12325759B2Anti-VEGF-anti-PD-L1 bispecific antibody, pharmaceutical composition of same, and uses thereofBIOTHEUS INC·Filed 2021·Granted Jun 10, 2025·0 cites·34 claims
- 0557US2022242968A1Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereofBIOTHEUS INC·Filed 2020·Application pending·0 cites
- 0656US2024417452A1Anti-mesothelin nanobodies and use thereofBIOTHEUS INC·Filed 2022·Application pending·0 cites
- 0756US2025122296A1Bispecific antibody and use thereofBIOTHEUS INC·Filed 2022·Application pending·0 cites
- 0854US12409233B2Anti-PD-L1 single-domain antibody and derivatives and use thereofBIOTHEUS INC·Filed 2020·Granted Sep 9, 2025·0 cites·10 claims
- 0953US2025230255A1Anti-cd39 nanobody and uses thereofBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 1053US2025223353A1Anti-pvrig antibody, pharmaceutical composition thereof and use thereofBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 1153US2025223354A1Anti-tigit-anti-pvrig bispecific antibody, pharmaceutical composition thereof and use thereofBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 1252US2025297009A1Anti-pd-1 monoclonal antibody, derivative thereof and use thereofBIOTHEUS INC·Filed 2023·Application pending·0 cites
- 1349US2023348627A1Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereofBIOTHEUS INC·Filed 2021·Application pending·0 cites
- 1448US2023357422A1Single-domain antibody targeting 4-1bb, fusion protein thereof, pharmaceutical composition and use thereofBIOTHEUS INC·Filed 2021·Application pending·0 cites
- 1548US2025345451A1Anti-pd-l1 single-domain antibody and derivatives and use thereofBIOTHEUS INC·Filed 2025·Application pending·0 cites
- 1647US2025019436A1Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use ThereofBIOTHEUS INC·Filed 2022·Application pending·0 cites
- 1747US2024352118A1Anti-tigit antibody and use thereofBIOTHEUS INC·Filed 2022·Application pending·0 cites
- 1845US12583933B2Anti-CD73 antibody and use thereofBIOTHEUS INC·Filed 2020·Granted Mar 24, 2026·0 cites·20 claims
- 1945US12565534B2Nano-antibody targeting CAIX antigen and application thereofBIOTHEUS INC·Filed 2020·Granted Mar 3, 2026·0 cites·13 claims
- 2045US2023167200A1Platform for constructing multispecific antibodyBIOTHEUS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →